Regencell Bioscience
3 hedge funds and large institutions have $156K invested in Regencell Bioscience in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
55% more capital invested
Capital invested by funds: $100K → $156K (+$55.4K)
50% more funds holding
Funds holding: 2 → 3 (+1)
3.93% more ownership
Funds ownership: 5.29% → 9.22% (+3.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$64.8K |
| 2 |
Morgan Stanley
New York
|
+$12K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $144K | +$64.8K | +430,996 | +63% |
|
|
2
Morgan Stanley
New York
| $10.4K | +$12K | +79,800 | New |
|
3
BlackRock
New York
| $1.18K | – | – | – |
|
RGC Hedge Fund Activity: Q4 2024 in Review
3 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q4 2024, worth a combined $156K — up 55% from $100K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new RGC positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $64.8K.
- 3 institutional investors held Regencell Bioscience (RGC) as of Q4 2024, up from 2 in Q3 2024.
- Funds reported $156K of Regencell Bioscience stock for Q4 2024, up 55% quarter-over-quarter.
- 1 fund opened new Regencell Bioscience positions in Q4 2024 and 0 closed out, a net change of +1 holder.
- The largest Regencell Bioscience buyer in Q4 2024 was UBS Group, an estimated $64.8K added.
Based on aggregated 13F filings for Q4 2024.